Palvella Therapeutics, Inc. · NASDAQ:PVLA

Palvella Therapeutics — Corporate Update (November 2026)

20 slides from Palvella Therapeutics's corporate update, Nov 19, 2026

  1. Slide 1: QTORIN Docetaxel: Developing the First Potential FDA-Approved Therapy for EMPD

    First-in-disease therapies for patients with rare skin diseases QTORIN™ Docetaxel: Developing the First Potential FDA-Approved Therapy for Extramammary Paget’s Disease November 19, 2026

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements of Palvella Therapeutics, Inc. (“the Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cas

  3. Slide 3: QTORIN Docetaxel for Extramammary Paget's Disease (EMPD)

    QTORIN™ Docetaxel for Extramammary Paget’s Disease (EMPD) Third product candidate developed from the QTORIN™ platform 1 Serious, Rare, No FDA-approved Therapies 2 QTORIN™ Innovation Applied to Clinically Validated Molecule 3 First for EMPD Patients Debilitating, life-threatening genital and perianal

  4. Slide 4: The Patient Perspective

    The Patient Perspective Steve Schroeder, Founder of myEMPD

  5. Slide 5: Living with EMPD: The Patient Perspective

    Living with EMPD: The Patient Perspective Patient and founder of myEMPD Advocates for EMPD awareness, community, and research Brings the patient voice to disease research and therapeutic development Connects with patients and clinicians around the world Life-threatening cancer affecting both women a

  6. Slide 6: Disease Overview & Scientific Rationale

    Disease Overview & Scientific Rationale Dr. Seemal R. Desai

  7. Slide 7: Dr. Seemal R. Desai, Board-Certified Dermatologist

    Dr. Seemal R. Desai, Board-Certified Dermatologist Seemal R. Desai, MD, FAAD Immediate past President of the American Academy of Dermatology (AAD), March 2024 - March 2025 Clinical Associate Professor of Dermatology – University of Texas Southwestern Medical Center Specializes in hard-to-treat vitil

  8. Slide 8: EMPD is a Rare Genital and Perianal Cancer with No FDA-Approved Therapy

    EMPD is a Rare Genital and Perianal Cancer with No FDA-Approved Therapy 1. Li et al. (2025) 2. Borghi et al. (2018) 3. Cavadas et al. (2022). Today Primary treatment is surgery Opportunity QTORIN™ docetaxel could transform the treatment paradigm to first-line topical therapy Scrotal EMPD1 Vulvar EMP

  9. Slide 9: EMPD Originates in Apocrine-Rich Skin and Progresses to Metastatic Disease

    Epidermis Dermis EMPD Originates in Apocrine-Rich Skin and Progresses to Metastatic Disease Paget Cells in Upper Epidermis1 In Situ Invasive Blood vessels <1mm deep Confined to the epidermis 1-4mm deep Risk of metastasis Paget cell: substantial size, abundant cytoplasm, eccentric nucleus 1. Shaco-Le

  10. Slide 10: QTORIN Docetaxel

    QTORIN™ Docetaxel Dr. Jeff Martini, Chief Scientific Officer Dr. David Osborne, Chief Innovation Officer

  11. Slide 11: Docetaxel: Human Clinical Evidence in EMPD

    Docetaxel: Human Clinical Evidence in EMPD DOCETAXEL MONOTHERAPY (n=93)1 51.6% ORR 24.7% discontinued due to adverse events 1. Miyashita et al. (2026) 2. Docetaxel has not been approved by the FDA for the treatment of EMPD. 52.7% ≥Grade 3 neutropenia A large and growing real-world evidence base, inc

  12. Slide 12: Docetaxel: An Established and Potent Anti-Cancer Agent

    Docetaxel: An Established and Potent Anti-Cancer Agent Locks microtubules in place, stopping dividing cells such as Paget cells Dividing cell Normal Locked Taxanes Stabilize Microtubules Normal: microtubules assemble and break down so the cell can divide Locked: docetaxel stabilizes them, so divisio

  13. Slide 13: QTORIN Docetaxel: Innovation Designed to Overcome Significant Formulation Barriers

    QTORIN™ Docetaxel: Innovation Designed to Overcome Significant Formulation Barriers By addressing docetaxel’s formulation challenges, QTORIN™ is designed to unlock its clinical and commercial potential in EMPD Hydrophobic Poor Skin Penetration Unstable QTORIN™ PLATFORM Skin-Targeted Stable Tunable D

  14. Slide 14: Milestones Achieved

    Milestones Achieved Selective penetration to the epidermis Favorable preliminary drug stability Payload fine-tuned to optimize tolerability Low systemic absorption anticipated IP: Filed formulation and method-of-use Using QTORIN™, we considered and tested multiple taxanes Molecule Potency Optimal Sk

  15. Slide 15: QTORIN Selectively Targets Disease in Epidermis

    Docetaxel 808 Da QTORIN™ Selectively Targets Disease in Epidermis Paget cell (dividing) Keratinocytes Docetaxel QTORIN™ In vitro skin penetration data per Palvella. Note: Docetaxel has not been approved by the FDA for the treatment of EMPD. 1 2 3 1 Break the 500 Da barrier Limit 500 Da 2 Concentrate

  16. Slide 16: QTORIN Docetaxel Clinical Development Plan

    QTORIN™ Docetaxel Clinical Development Plan FDA meeting planned 1H 2027 QTORIN™ Docetaxel: From Concept to Clinic Leveraging 505(b)(2) pathway Following pre-IND meeting, Palvella plans to advance to a Phase 2 study IND-enabling study activities initiated

  17. Slide 17: QTORIN Docetaxel EMPD Aligns with Palvella's Pipeline Strategy

    QTORIN™ Rapamycin / Pitavastatin Rare Serious Strong Scientific & Biologic Rationale Commercially Attractive No FDA-approved Therapies Highly debilitating and life-threatening cancer >10k U.S. patients2 Docetaxel stabilizes microtubules, preventing cell division and inducing apoptosis None mLMs, cVM

  18. Slide 18: Key Takeaways

    Key Takeaways Wes Kaupinen Founder & Chief Executive Officer

  19. Slide 19: Slide 19

  20. Slide 20: Thank You

    Striving to be first for rare disease patients Thank You

Palvella Therapeutics — Corporate Update (November 2026) on 6ix